Repligen Corp (RGEN) Financial Statements
Historical financial data — 39 statements covering FY2016–FY2025
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, includ...
Repligen Corp's revenue increased 16.4% year over year, from $634.4M to $738.3M.
Net income increased 291.6% over the same period, from $-25.5M to $48.9M.
Over the 9-year period from FY2016 to FY2025, revenue grew by 606% in total.
Total debt decreased by 25.7% to $542.2M.
The debt-to-equity ratio stands at 0.26, indicating a conservative leverage profile.
Operating cash flow declined 33.1% to $117.4M.
Repligen Corp maintains a moderate net profit margin of 6.6%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2024 | $305.4M+116.3% | $5.4M | $151.7M | $3.5M | $86.9M | $2.86B | $701.3M | $1.99B |
| Q3 FY2024 | $161.5M-47.1% | $2.9M | $84.1M | $-2.1M | $49.3M | $2.83B | $705.6M | $2.02B |
| Q4 FY2024 | $167.5M+3.8% | $-33.9M | $38.8M | $-36.5M | $39.2M | $2.83B | $730.2M | $1.97B |
| Q1 FY2025 | $169.2M+1.0% | $5.8M | $90.8M | $6.6M | $15.0M | $2.85B | $714.7M | $1.99B |
| Q2 FY2025 | $182.4M+7.8% | $14.9M | $91.1M | $13.9M | $28.6M | $2.90B | $716.9M | $2.06B |
| Q3 FY2025 | $188.8M+3.5% | $14.9M | $100.5M | $16.8M | $48.1M | $2.92B | $537.9M | $2.08B |
| Q4 FY2025 | $197.9M+4.8% | $13.3M | $103.8M | $17.9M | $25.7M | $2.95B | $542.2M | $2.11B |
| Q1 FY2026 | $194.3M-1.8% | $8.3M | $108.3M | $15.9M | $28.3M | $2.93B | $546.6M | $2.11B |
Balance Sheet Summary (Latest Period)
Repligen Corp (RGEN) Financial Statements & Revenue History
Repligen Corp (RGEN) is a US-listed stock operating in the Healthcare sector, specifically the Biological Products, (No Diagnostic Substances) industry trading at $189.68 with a market capitalization of $11. This page provides 39 historical financial statements for Repligen Corp, including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, Repligen Corp reported revenue of $738 million, representing 16.4% year-over-year growth. The net profit margin of 6.6% indicates moderate profitability. The debt-to-equity ratio of 0.26 shows conservative leverage.
RGEN Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows Repligen Corp's revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether RGEN is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track RGEN's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently Repligen Corp converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of RGEN's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use RGEN Financial Data
Investors use Repligen Corp's financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare RGEN's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how RGEN's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View RGEN's financial health score, earnings, and pre-market pricing.
Financial data is sourced from Repligen Corp's SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.RGEN trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.